To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open-
High-
Low-
Prev. Close-
Avg. Traded Price-
Volume-

MARKET DEPTH

info2
Total bid0.00
Total ask0.00
OrdersQtyBid
AskQtyOrders

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

507.05a day ago
529.8020 hours ago
arrow

LOWER/UPPER CIRCUITS

414.25
621.35
arrow
Aarti Drugs Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
notePrice to Earning Ratio,is 25.29, lower than its sector PE ratio of 43.7.
noteQuarterly Revenue,rose 6.33% YoY to ₹590.82 Cr. Its sector's average revenue growth YoY for the quarter was 11.41%.
noteQuarterly Net profit,rose 62.18% YoY to ₹53.91 Cr. Its sector's average net profit growth YoY for the quarter was 37.72%.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 22.21%
Net profit growth 5Y CAGR : 13.84%
Aarti Drugs Ltd Top mutual funds holding
arrow
Aarti Drugs Limited was established in the year 1984 and forms part of Aarti Group of Industries with robust RD Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited. Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.
personal

Grow your wealth with more research recommendations

+91